Stryker vs Thermo Fisher Scientific stock
Side by side in plain words: who keeps more of its sales, grows faster, costs less and owes less.
Stryker grows faster, is cheaper for its profits and has less debt. Thermo Fisher Scientific is more profitable.
Side by side
| Stryker | Thermo Fisher Scientific | |
|---|---|---|
| $118 billion | $259 billion | |
| 12.9% | 15.0% | |
| +11.8% | +6.7% | |
| 36.3× | 38.7× | |
| 1.9 years | 2.6 years | |
| 10.8% | 7.6% | |
| 1.1% | 0.4% |
How we compare
Four contests with the same rules as each stock page: profit kept from sales (higher wins), yearly sales growth across the last reports, up to five years (higher wins), price per unit of yearly profit (lower P/E wins; a company without profit loses) and debt in years of earnings (lower wins). A winner is only named when both companies have the number.
More comparisons: Stryker vs UnitedHealth · Stryker vs AbbVie · Stryker vs Boston Scientific · Stryker vs Johnson & Johnson · Thermo Fisher Scientific vs Trimble · Thermo Fisher Scientific vs AbbVie · Thermo Fisher Scientific vs Amgen · Thermo Fisher Scientific vs Bristol-Myers Squibb

